Docoh
Loading...

HOTH Hoth Therapeutics

Filed: 15 Apr 21, 8:00am

 

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

  

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) April 12, 2021

 

Hoth Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

  

Nevada 001-38803 82-1553794
(State or other jurisdiction
of incorporation)
 (Commission File Number) (I. R. S. Employer
Identification No.)

 

1 Rockefeller Plaza, Suite 1039

New York, New York 10020

(Address of principal executive offices, including ZIP code)

 

(646) 756-2997

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, $0.0001 par value HOTH The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

  

 

 

Item 8.01 Other Events.

 

On April 13, 2021, Hoth Therapeutics, Inc. (the “Company”) received confirmation of the filing of international patent applications in China and Japan based upon a patent application with the United States Patent and Trademark Office for the use of one of its current portfolio therapeutics to treat and prevent asthma and anaphylactic shock. The Company has an exclusive license agreement with respect to the use of this drug from North Carolina State University.

 

In addition, on April 12, 2021, the Company received confirmation that the filing of the assignment of ownership of the provisional patent application for the use of one of its current portfolio therapeutics to treat and prevent Alzheimer’s disease has been recorded in the United States Patent and Trademark Office. The Company has an exclusive license agreement with respect to the use of this drug for other indications.

 

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is associated with the destruction of higher brain structures, such as those involved in memory and cognition. The disease leads to deficits in cognitive function and declines in memory, learning, language, and in the ability to perform intentional and purposeful movements. AD is also accompanied by concomitant behavioral, emotional, interpersonal, and social deterioration. These cognitive and behavioral deficits render living difficult. Late-stage AD patients are often unable to speak, comprehend language, and handle their own basic personal care, eventually requiring full-time care and supervision, and are often dependent on family members and nursing homes. AD is the leading cause of senile dementia, and is predicted to increase in prevalence as the proportion of elderly persons in the population grows. The total number of persons with AD is predicted to increase at least threefold between 2000 and 2050, rendering AD a world-wide public health problem. Clinical detection, management, and treatment of AD remains largely inadequate. There is still an unmet need for effective methods to prevent and treat AD. 

 2 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

Date: April 15, 2021Hoth Therapeutics, Inc.
  
 By: /s/ Robb Knie
  Robb Knie
Chief Executive Officer

 

3